Vaxart Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Vaxarthan disminuido a un ritmo medio anual de -40.6%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido declining a una tasa media anual de 37.6%.

Información clave

-37.1%

Tasa de crecimiento de los beneficios

30.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-32.1%
Rentabilidad financiera	-142.7%
Margen neto	-1,117.6%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Vaxart: An Update

Oct 02

Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth

Aug 25

Vaxart: World's First Oral COVID Vaccine In Development

Jul 25

FDA is set to decline new emergency use authorizations for COVID-19 vaccines

May 26

We're Hopeful That Vaxart (NASDAQ:VXRT) Will Use Its Cash Wisely

May 11

Enrollment underway in Vaxart's early-stage norovirus trial in elderly population

May 07

Vaxart EPS misses by $0.04, misses on revenue

May 03

Plucky Underdog Vaxart Still Banging Drum For Oral Vaccination

Apr 30

Vaxart is soaring on more than 10 times the two-month average volume

Apr 27

Shareholders Are Thrilled That The Vaxart (NASDAQ:VXRT) Share Price Increased 231%

Mar 03

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Vaxart. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:VXRT Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	7	-82	23
30 Sep 23	4	-89	24
30 Jun 23	2	-101	26
31 Mar 23	1	-108	29
31 Dec 22	0	-108	29
30 Sep 22	0	-105	29
30 Jun 22	0	-93	27
31 Mar 22	0	-80	23
31 Dec 21	1	-70	22
30 Sep 21	1	-64	21
30 Jun 21	1	-54	20
31 Mar 21	2	-47	19
31 Dec 20	4	-32	15
30 Sep 20	8	-25	11
30 Jun 20	8	-22	9
31 Mar 20	7	-19	6
31 Dec 19	10	-19	6
30 Sep 19	8	-17	6
30 Jun 19	8	-18	6
31 Mar 19	8	-22	7
31 Dec 18	4	-18	7
30 Sep 18	3	-15	6
30 Jun 18	4	-12	5
31 Mar 18	5	-7	3
31 Dec 17	6	-12	3
30 Sep 17	9	-16	3
31 Dec 16	8	-19	3
31 Dec 15	0	-22	3

Ingresos de calidad: VXRT actualmente no es rentable.

Margen de beneficios creciente: VXRT actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: VXRT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 40.6% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de VXRT en el último año con su media de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: VXRT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).

Rentabilidad financiera

Alto ROE: VXRT tiene un Rendimiento de los fondos propios negativo (-124.45%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Vaxart Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)

Recent updates

Now 27% overvalued after recent price rise

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Consensus revenue estimates increase by 57%

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

New major risk - Share price stability

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Consensus revenue estimates decrease by 60%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Price target decreased to US$7.75

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Ray Stapleton joins Vaxart as CTO

Vaxart, Inc. Announces Board Changes

Consensus revenue estimates fall by 12%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Price target decreased to US$9.75

Vaxart shareholders approve proposal to increase number of shares

Vaxart continues to lobby shareholders to vote to increase number of shares

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Vaxart: A Unique Vaccine Concern

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Price target decreased to US$11.40

Consensus revenue estimates fall by 82%

Vaxart, Inc. Announces Management Changes

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Price target decreased to US$11.60

High number of new and inexperienced directors

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

Price target decreased to US$12.00

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

Forecast to breakeven in 2024

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc.

No longer forecast to breakeven

Vaxart: Differentiated Covid Oral Route Remains Viable

Desglose de ingresos y gastos
Beta